MétaCan
Menu
← Back to cohort
Record W4237565189 · doi:10.1155/2004/681760

6th Canadian Immunization Conference: <i>Immunization in Canada</i>

2004· article· en· W4237565189 on OpenAlexaffabout
Shelly McNeil, Joanne M. Langley, Bruce R. Smith, Rehana Abdullah Sani, G Lund, AJ Malcolm, Scott A. Halperin, Shelley L. Deeks, M. A. Clark, David W. Scheifele, B Law, Meena Dawar, N Ahmadipour, Wikke Walop, A King, Philippe De Wals, Geneviève Deceuninck, Nicole Boulianne, Gaston De Serres, L Cook, Raymond S. W. Tsang, Shaun Tyler, David S. Law, J.F. Stoltz, A Henderson, Sarah E. Wilson, Helen M. Kent, Kami Kandola, Lea Azour, Márcio Silva Santos Júnior

Bibliographic record

VenueCanadian Journal of Infectious Diseases and Medical Microbiology · 2004
Typearticle
Languageen
FieldSocial Sciences
TopicVaccine Coverage and Hesitancy
Canadian institutionsDalhousie UniversityIzaak Walton Killam Health CentreHealth CanadaGovernment of Northwest Territories
Fundersnot available
KeywordsImmunizationMedicineVirologyFamily medicineImmunologyAntibody

Abstract

fetched live from OpenAlex

Introduction: P. aeruginosa (PA) is a leading cause of nosocomial infections, affecting approximately 1 in 5 patients in intensive care units.Patients with cystic fibrosis, cancer, solid organ transplant or burns are at high risk for serious PA infection.An effective prophylactic vaccine could reduce morbidity and mortality in these groups.Methods: We conducted a Phase I dose-escalation trial of Cytovaxine, a synthetic consensus sequence pilin peptide conjugated to tetanus toxoid (TT) plus alum, in 35 healthy adult volunteers.Subjects were screened for good general health and had saliva, blood, and nasal washes collected for baseline antibody titres.Three vaccine doses were evaluated: 15 µg conjugate vaccine (CV)-2.5 Lf TT, 30 µg CV-5 Lt TT, and 60 µg CV-10 Lf TT.Dose escalation was permitted after review of the 6-week safety data following each dose level.Subjects were randomized within each dose level to receive either CV or TT plus alum control, and intramuscular injections were given on days 0, 42, and 140 with clinical and laboratory follow-up for safety and anti-consensus sequence peptide antibody titres.Results: Study injections were well tolerated and no safety concerns were raised.No serious adverse events (AEs) occurred.Mild tenderness at the injection site and mild pain with arm movement were the most commonly reported AEs; these events were similar between the study vaccine and the control.A mild systemic AE was reported by 40%-80% of subjects after one or more doses.Mild muscle aches were commonly reported (0%-40%) but were more common in the control arms; headaches were common in all groups but more common following the third 30 µg vaccine dose.Fever was not reported by any subject and no pattern of abnormal results was noted in clinical chemistry, hematology, or urinalysis.An IgG anti-consensus sequence antibody response was seen at all dose levels; there was no apparent dose-response effect.Forty to 50% of subjects in the three consensus sequence immunized group had a 2-fold rise in antibody titre and 30%-50% had a 4-fold rise.Little IgA or IgM response was demonstrated and there were no increases in salivary or nasal wash anticonsensus sequence antibody in any group.Conclusions: The PA study vaccine was safe and well tolerated in this Phase 1 trial.Immunogenicity was modest and further study is warranted.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Other · Consensus signal: Other
Teacher disagreement score0.116
Threshold uncertainty score0.267

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.003
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.001
Science and technology studies0.0030.001
Scholarly communication0.0030.001
Open science0.0020.001
Research integrity0.0060.003
Insufficient payload (model declined to judge)0.0800.018

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.005
GPT teacher head0.217
Teacher spread0.212 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreOther

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2004
Admission routes2
Has abstractyes

Explore more

Same venueCanadian Journal of Infectious Diseases and Medical Microbiology→Same topicVaccine Coverage and Hesitancy→French-language works237,207→